drugset
Drugs / V-01-351/V-01D Bivalence Vaccine
last change Jan 2023 re-read 3 minutes ago

V-01-351/V-01D Bivalence Vaccine

Vaccine

Developed for
COVID-19
Investigated by
Livzon Pharmaceutical Group Inc.

Trials 1

today NCT05273528 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05273528 Jan 2022 → Jan 2023 COVID-19 Livzon Pharmaceutical Group Inc. Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as V-01-351/V-01D Bivalence Vaccine “The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine” NCT05273528 ↗
Modality Vaccine “V-01-351/V-01D Bivalence Vaccine” NCT05273528 ↗